Patents by Inventor Venkata P. Palle
Venkata P. Palle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9969731Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: GrantFiled: December 22, 2016Date of Patent: May 15, 2018Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9944639Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.Type: GrantFiled: July 1, 2015Date of Patent: April 17, 2018Assignee: Lupin LimitedInventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9827247Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.Type: GrantFiled: January 6, 2017Date of Patent: November 28, 2017Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20170304299Abstract: The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).Type: ApplicationFiled: July 6, 2017Publication date: October 26, 2017Inventors: Nageswara Rao IRLAPATI, Gokul Keruji DESHMUKH, Vijay Pandurang KARCHE, Santosh Madhukar JACHAK, Neelima SINHA, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Patent number: 9790231Abstract: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators.Type: GrantFiled: June 23, 2014Date of Patent: October 17, 2017Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Kiran Chandrashekhar Kulkarni, Vijay Pandurang Karche, Gokul Keruji Deshmukh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9737534Abstract: The present invention relates to compounds of Formula (I), along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).Type: GrantFiled: August 31, 2015Date of Patent: August 22, 2017Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Gokul Keruji Deshmukh, Vijay Pandurang Karche, Santosh Madhukar Jachak, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9725463Abstract: The invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine for the treatment of diseases, disorders associated with the modulation of calcium release-activated calcium (CRAC) channel. The invention also relates to pharmaceutical compositions containing such compounds in treating diseases disorders associated with calcium release-activated calcium (CRAC) channel modulators. wherein, ring D is Formula (a) or Formula (b): A and B, which may be same or different, are independently CR3 or N; Y is CR3 or N; L is selected from —NR2C(O)—, —C(O)NR2— and —NR2CRaRb—; Ra and Rb are independently hydrogen, halogen or substituted or unsubstituted alkyl; ring E is selected from the Formula (i) to (vii).Type: GrantFiled: June 20, 2014Date of Patent: August 8, 2017Assignee: LUPIN LIMITEDInventors: Nageswara Rao Irlapati, Nilesh Raghunath Khedkar, Ravindra Babanrao Jape, Rahul Shripad Nandurdikar, Zubair Abdul Wajid Shaikh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20170209410Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.Type: ApplicationFiled: January 26, 2017Publication date: July 27, 2017Inventors: Manojkumar Ramprasad SHUKLA, Ankush Gangaram SARDE, Rajeshkumar Maganlal LORIYA, Vipul Dilip PACHPUTE, Navnath Bajirao WALKE, Talha Hussain KHAN, Sanjeev Anant KULKARNI, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20170137421Abstract: Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein R1-R4, and n are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PI3K enzyme of a subject.Type: ApplicationFiled: July 1, 2015Publication date: May 18, 2017Applicant: Lupin LimitedInventors: Manojkumar Ramprasad Shukla, Nirmal Kumar Jana, Sachin Jaysing Mahangare, Prashant Popatrao Vidhate, Dipak Raychand Lagad, Anand Jagannath Tarage, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
-
Publication number: 20170137415Abstract: The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.Type: ApplicationFiled: March 27, 2015Publication date: May 18, 2017Inventors: Vidya RAMDAS, Rajeshkumar Maganlal LORIYA, Deepak Sahebrao WALKE, Amit Kumar DAS, Talha Hussain KHAN, Moloy BANERJEE, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20170137371Abstract: The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Inventors: Manojkumar Ramprasad Shukla, Vinod Dinkar Chaudhari, Ankush Gangaram Sarde, Ramesh Dattatraya Phadtare, Mahadeo Bhaskar Tryambake, Dronamraju Prameela, Sanjeev Anant Kulkarni, Rajender Kumar Kamboj, Venkata P. Palle
-
Publication number: 20170112840Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.Type: ApplicationFiled: January 6, 2017Publication date: April 27, 2017Applicant: LUPIN LIMITEDInventors: Bhavesh DAVE, Rakesh Kumar BANERJEE, Samiron PHUKAN, Abhijit Datta KHOJE, Rajkumar HANGARGE, Jitendra Sambhaji JADHAV, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20170101408Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: ApplicationFiled: December 22, 2016Publication date: April 13, 2017Applicant: LUPIN LIMITEDInventors: Bhavesh DAVE, Rakesh Kumar BANERJEE, Samiron PHUKAN, Abhijit Datta KHOJE, Rajkumar HANGARGE, Jitendra Sambhaji JADHAV, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Patent number: 9617211Abstract: Disclosed is a compound of formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as a modulator of nicotinic acetylcholine receptors particularly ?7 subtype, its tautomeric forms, its stereoisomers, its pharmaceutically acceptable salts, its pharmaceutical composition, and its combinations with suitable medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.Type: GrantFiled: January 13, 2014Date of Patent: April 11, 2017Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Anil Kashiram Hajare, Baban Rupaji Thube, Dnyaneshwar Changdeo Bhanage, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9617210Abstract: Disclosed are compounds of the Formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the ?7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia.Type: GrantFiled: March 12, 2014Date of Patent: April 11, 2017Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Shridhar Keshav Adurkar, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9598391Abstract: The present invention provides calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.Type: GrantFiled: September 1, 2015Date of Patent: March 21, 2017Assignee: Lupin Atlantis Holdings SAInventors: Manojkumar Ramprasad Shukla, Ankush Gangaram Sarde, Rajeshkumar Maganlal Loriya, Vipul Dilip Pachpute, Navnath Bajirao Walke, Talha Hussain Khan, Sanjeev Anant Kulkarni, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9598371Abstract: The present invention provides arylalkylamine compounds as calcium sensing receptor modulators (CaSR). In particular, the compounds described herein are useful for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of calcium sensing receptors (CaSR). The invention also provides herein the pharmaceutical compositions thereof, and methods for treating, managing, and/or lessening the severity of diseases, disorders, syndromes and/or conditions associated with the modulation of CaSR. The invention also relates to process for the preparation of the compounds of the invention.Type: GrantFiled: November 25, 2015Date of Patent: March 21, 2017Assignee: LUPIN ATLANTIS HOLDINGS SAInventors: Manojkumar Ramprasad Shukla, Vinod Dinkar Chaudhari, Ankush Gangaram Sarde, Ramesh Dattatraya Phadtare, Mahadeo Bhaskar Tryambake, Dronamraju Prameela, Sanjeev Kulkarni, Rajender Kumar Kamboj, Venkata P. Palle
-
Patent number: 9573944Abstract: The present invention is related to heteroaryl compounds as MEK inhibitors. The invention includes heteroaryl compounds of formula I, their tautomers and pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present invention also includes process of preparation of the said compounds and intended use in therapy of them.Type: GrantFiled: March 11, 2013Date of Patent: February 21, 2017Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9555035Abstract: The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment.Type: GrantFiled: July 25, 2016Date of Patent: January 31, 2017Assignee: Lupin LimitedInventors: Bhavesh Dave, Rakesh Kumar Banerjee, Samiron Phukan, Abhijit Datta Khoje, Rajkumar Hangarge, Jitendra Sambhaji Jadhav, Venkata P. Palle, Rajender Kumar Kamboj
-
Patent number: 9504680Abstract: Disclosed are compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7 and m are as described herein, as modulators of the nicotinic acetylcholine receptors, particularly the ?7 subtype, their tautomeric forms, stereoisomers, and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, and combinations thereof with suitable other medicaments. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and/or treatment of disorders such as Alzheimer's disease, mild cognitive impairment, and senile dementia.Type: GrantFiled: June 16, 2014Date of Patent: November 29, 2016Assignee: Lupin LimitedInventors: Neelima Sinha, Navnath Popat Karche, Shridhar Keshav Adurkar, Dnyaneshwar Changdeo Bhanage, Venkata P. Palle, Rajender Kumar Kamboj